

# **Vulvar Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Cancer Type (Vulvar Squamous Cell Carcinoma, Vulvar Melanoma, Adenocarcinoma, Basal Cell Carcinoma), By Treatment Type (Chemotherapy, Surgery, Laser Surgery, Excision, Skinning Vulvectomy, Radical Vulvectomy, Radiation Vulvectomy, Biologic Therapy), By End-User (Hospitals & Clinics, Research & Academic Institutes, Others), By Region & Competition, 2021-2031F**

<https://marketpublishers.com/r/V19E8D03A277EN.html>

Date: January 2026

Pages: 180

Price: US\$ 4,500.00 (Single User License)

ID: V19E8D03A277EN

## **Abstracts**

The Global Vulvar Cancer Market is projected to increase from USD 650.78 Million in 2025 to USD 940.52 Million by 2031, registering a CAGR of 6.33%. This market comprises diagnostic technologies and therapeutic interventions, such as surgery, chemotherapy, and immunomodulators, designed to manage vulvar malignancies. Key factors driving this growth include an aging female population increasingly prone to vulvar neoplasia and a rising incidence of Human Papillomavirus infections, which are a primary cause of squamous cell carcinomas. Additionally, strong government programs focused on improving women's health are boosting early detection rates, thereby increasing the number of patients requiring timely medical treatment.

However, the market faces significant hurdles due to the high cost of advanced biologic therapies and the severe side effects often associated with radical surgical procedures. These financial and clinical barriers can discourage patient compliance and restrict market reach in developing nations with limited healthcare budgets. According to the

American Cancer Society, approximately 7,480 new cases of vulvar cancer are expected to be diagnosed in the United States in 2025. This figure highlights the persistent burden of the disease, underscoring the need for manufacturers to focus on developing cost-effective and well-tolerated treatment innovations.

### **Market Driver**

The Global Vulvar Cancer Market is being significantly transformed by a strong pipeline of novel immunotherapies and targeted agents, providing new prospects for patients with advanced or recurrent conditions. Pharmaceutical developers are prioritizing immune checkpoint inhibitors to surpass the limitations of traditional chemoradiation, thereby improving efficacy for complex cases. For example, Targeted Oncology reported in June 2025, in the article 'Pembrolizumab Combo Promising for Unresectable Vulvar Cancer', that a recent phase 2 clinical trial showed a 75% objective response rate in patients with locally advanced, unresectable squamous cell carcinoma when treated with a combination of pembrolizumab, cisplatin, and radiation. This rise in effective biologic agents is fueling market growth by widening the eligible patient base and promoting the adoption of premium therapeutic regimens.

Simultaneously, the increasing prevalence of Human Papillomavirus (HPV) infections acts as a major catalyst for market expansion, creating a need for improved preventative and therapeutic strategies. As infection rates endure, particularly among younger populations, the rise in HPV-linked malignancies continues to elevate the demand for specialized oncological care. The Centers for Disease Control and Prevention (CDC) noted in its December 2025 report 'Cancers Associated with Human Papillomavirus' that HPV is now estimated to cause approximately 69% of all vulvar cancers. This strong causal link emphasizes the urgent need for targeted interventions and strict screening programs; furthermore, the American Cancer Society estimates that 1,770 women in the United States will die from vulvar cancer in 2025, reinforcing the critical necessity for the continued development of advanced diagnostic and therapeutic solutions.

### **Market Challenge**

The prohibitive costs associated with biologic therapies represent a major barrier to the expansion of the Global Vulvar Cancer Market. The high pricing structures of these agents create substantial economic obstacles, particularly in developing regions where healthcare budgets are constrained. When advanced treatments remain financially inaccessible, market penetration is severely curtailed, preventing manufacturers from

optimizing revenue within these demographics. Consequently, the market struggles to achieve broad adoption, limiting its growth primarily to affluent segments rather than addressing the needs of the wider global patient population.

This economic restriction is compounded by clinical deterrents associated with radical surgical procedures, which frequently carry risks of severe side effects. Collectively, these factors create a gap between the prevalence of the disease and the utilization of available therapeutic interventions. This disparity is underscored by mortality data suggesting that current market mechanisms are not fully alleviating the disease burden. According to the American Cancer Society, approximately 1,770 deaths were projected to result from vulvar cancer in the United States in 2025. This statistic indicates that despite available technologies, economic and clinical hurdles continue to impede the successful delivery of care, directly hampering market growth.

## **Market Trends**

The Global Vulvar Cancer Market is experiencing significant advancement in sentinel lymph node (SLN) mapping and biopsy protocols, shifting from traditional dye-based methods to fluorescence-guided techniques that reduce surgical morbidity. Clinicians are increasingly adopting indocyanine green (ICG) tracers to enhance the precision of nodal staging, thereby minimizing the incidence of lymphedema associated with complete lymphadenectomy. This transition is supported by compelling clinical data; according to *Physician's Weekly* in May 2025, in the article 'Indocyanine Green Matches Dual Tracers in Vulvar SLN Detection', a systematic review found that the per-patient sentinel lymph node detection rate for indocyanine green was 88%, proving it to be a highly effective and less invasive alternative to standard radiotracers.

Concurrently, the implementation of genomic profiling for personalized treatment plans is reshaping the therapeutic landscape, particularly for HPV-independent tumors which have historically lacked targeted options. Medical centers are incorporating next-generation sequencing into routine diagnostic workflows to identify actionable somatic mutations, facilitating the stratification of patients for emerging precision medicine therapies. This trend is substantiated by recent molecular characterization efforts; as reported by the *International Journal of Gynecological Cancer* in December 2024, in the article 'Molecular and microenvironmental landscapes of human papillomavirus-independent invasive squamous cell carcinoma of the vulva', targeted sequencing revealed recurrent somatic mutations affecting TP53 in 68% of the studied cases, highlighting its potential as a critical biomarker for therapeutic selection.

## Key Market Players

Merck & Co. Inc.

Sanofi SA

Novartis AG

Astellas Pharma Inc.

Pfizer Inc.

Abbott Laboratories

Bristol-Myers Squibb Company

Takeda Pharmaceutical Company Limited

F. Hoffmann-La Roche Ltd

Eli Lilly and Company

## Report Scope

In this report, the Global Vulvar Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Vulvar Cancer Market, By Cancer Type

Vulvar Squamous Cell Carcinoma

Vulvar Melanoma

Adenocarcinoma

Basal Cell Carcinoma

Vulvar Cancer Market, By Treatment Type

Chemotherapy

Surgery

Laser Surgery

Excision

Skinning Vulvectomy

Radical Vulvectomy

Radiation Vulvectomy

Biologic Therapy

#### Vulvar Cancer Market, By End-User

Hospitals & Clinics

Research & Academic Institutes

Others

#### Vulvar Cancer Market, By Region

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

## **Competitive Landscape**

Company Profiles: Detailed analysis of the major companies present in the Global Vulvar Cancer Market.

**Available Customizations:**

Global Vulvar Cancer Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

**Company Information**

Detailed analysis and profiling of additional market players (up to five).

## Contents

### 1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
  - 1.2.1. Markets Covered
  - 1.2.2. Years Considered for Study
  - 1.2.3. Key Market Segmentations

### 2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

### 3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

### 4. VOICE OF CUSTOMER

### 5. GLOBAL VULVAR CANCER MARKET OUTLOOK

- 5.1. Market Size & Forecast
  - 5.1.1. By Value
- 5.2. Market Share & Forecast
  - 5.2.1. By Cancer Type (Vulvar Squamous Cell Carcinoma, Vulvar Melanoma, Adenocarcinoma, Basal Cell Carcinoma)
  - 5.2.2. By Treatment Type (Chemotherapy, Surgery, Laser Surgery, Excision, Skinning Vulvectomy, Radical Vulvectomy, Radiation Vulvectomy, Biologic Therapy)

- 5.2.3. By End-User (Hospitals & Clinics, Research & Academic Institutes, Others)
- 5.2.4. By Region
- 5.2.5. By Company (2025)
- 5.3. Market Map

## **6. NORTH AMERICA VULVAR CANCER MARKET OUTLOOK**

- 6.1. Market Size & Forecast
  - 6.1.1. By Value
- 6.2. Market Share & Forecast
  - 6.2.1. By Cancer Type
  - 6.2.2. By Treatment Type
  - 6.2.3. By End-User
  - 6.2.4. By Country
- 6.3. North America: Country Analysis
  - 6.3.1. United States Vulvar Cancer Market Outlook
    - 6.3.1.1. Market Size & Forecast
      - 6.3.1.1.1. By Value
    - 6.3.1.2. Market Share & Forecast
      - 6.3.1.2.1. By Cancer Type
      - 6.3.1.2.2. By Treatment Type
      - 6.3.1.2.3. By End-User
  - 6.3.2. Canada Vulvar Cancer Market Outlook
    - 6.3.2.1. Market Size & Forecast
      - 6.3.2.1.1. By Value
    - 6.3.2.2. Market Share & Forecast
      - 6.3.2.2.1. By Cancer Type
      - 6.3.2.2.2. By Treatment Type
      - 6.3.2.2.3. By End-User
  - 6.3.3. Mexico Vulvar Cancer Market Outlook
    - 6.3.3.1. Market Size & Forecast
      - 6.3.3.1.1. By Value
    - 6.3.3.2. Market Share & Forecast
      - 6.3.3.2.1. By Cancer Type
      - 6.3.3.2.2. By Treatment Type
      - 6.3.3.2.3. By End-User

## **7. EUROPE VULVAR CANCER MARKET OUTLOOK**

- 7.1. Market Size & Forecast
  - 7.1.1. By Value
- 7.2. Market Share & Forecast
  - 7.2.1. By Cancer Type
  - 7.2.2. By Treatment Type
  - 7.2.3. By End-User
  - 7.2.4. By Country
- 7.3. Europe: Country Analysis
  - 7.3.1. Germany Vulvar Cancer Market Outlook
    - 7.3.1.1. Market Size & Forecast
      - 7.3.1.1.1. By Value
    - 7.3.1.2. Market Share & Forecast
      - 7.3.1.2.1. By Cancer Type
      - 7.3.1.2.2. By Treatment Type
      - 7.3.1.2.3. By End-User
  - 7.3.2. France Vulvar Cancer Market Outlook
    - 7.3.2.1. Market Size & Forecast
      - 7.3.2.1.1. By Value
    - 7.3.2.2. Market Share & Forecast
      - 7.3.2.2.1. By Cancer Type
      - 7.3.2.2.2. By Treatment Type
      - 7.3.2.2.3. By End-User
  - 7.3.3. United Kingdom Vulvar Cancer Market Outlook
    - 7.3.3.1. Market Size & Forecast
      - 7.3.3.1.1. By Value
    - 7.3.3.2. Market Share & Forecast
      - 7.3.3.2.1. By Cancer Type
      - 7.3.3.2.2. By Treatment Type
      - 7.3.3.2.3. By End-User
  - 7.3.4. Italy Vulvar Cancer Market Outlook
    - 7.3.4.1. Market Size & Forecast
      - 7.3.4.1.1. By Value
    - 7.3.4.2. Market Share & Forecast
      - 7.3.4.2.1. By Cancer Type
      - 7.3.4.2.2. By Treatment Type
      - 7.3.4.2.3. By End-User
  - 7.3.5. Spain Vulvar Cancer Market Outlook
    - 7.3.5.1. Market Size & Forecast
      - 7.3.5.1.1. By Value

#### 7.3.5.2. Market Share & Forecast

##### 7.3.5.2.1. By Cancer Type

##### 7.3.5.2.2. By Treatment Type

##### 7.3.5.2.3. By End-User

## **8. ASIA PACIFIC VULVAR CANCER MARKET OUTLOOK**

### 8.1. Market Size & Forecast

#### 8.1.1. By Value

### 8.2. Market Share & Forecast

#### 8.2.1. By Cancer Type

#### 8.2.2. By Treatment Type

#### 8.2.3. By End-User

#### 8.2.4. By Country

### 8.3. Asia Pacific: Country Analysis

#### 8.3.1. China Vulvar Cancer Market Outlook

##### 8.3.1.1. Market Size & Forecast

###### 8.3.1.1.1. By Value

##### 8.3.1.2. Market Share & Forecast

###### 8.3.1.2.1. By Cancer Type

###### 8.3.1.2.2. By Treatment Type

###### 8.3.1.2.3. By End-User

#### 8.3.2. India Vulvar Cancer Market Outlook

##### 8.3.2.1. Market Size & Forecast

###### 8.3.2.1.1. By Value

##### 8.3.2.2. Market Share & Forecast

###### 8.3.2.2.1. By Cancer Type

###### 8.3.2.2.2. By Treatment Type

###### 8.3.2.2.3. By End-User

#### 8.3.3. Japan Vulvar Cancer Market Outlook

##### 8.3.3.1. Market Size & Forecast

###### 8.3.3.1.1. By Value

##### 8.3.3.2. Market Share & Forecast

###### 8.3.3.2.1. By Cancer Type

###### 8.3.3.2.2. By Treatment Type

###### 8.3.3.2.3. By End-User

#### 8.3.4. South Korea Vulvar Cancer Market Outlook

##### 8.3.4.1. Market Size & Forecast

###### 8.3.4.1.1. By Value

- 8.3.4.2. Market Share & Forecast
  - 8.3.4.2.1. By Cancer Type
  - 8.3.4.2.2. By Treatment Type
  - 8.3.4.2.3. By End-User
- 8.3.5. Australia Vulvar Cancer Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Cancer Type
    - 8.3.5.2.2. By Treatment Type
    - 8.3.5.2.3. By End-User

## **9. MIDDLE EAST & AFRICA VULVAR CANCER MARKET OUTLOOK**

- 9.1. Market Size & Forecast
  - 9.1.1. By Value
- 9.2. Market Share & Forecast
  - 9.2.1. By Cancer Type
  - 9.2.2. By Treatment Type
  - 9.2.3. By End-User
  - 9.2.4. By Country
- 9.3. Middle East & Africa: Country Analysis
  - 9.3.1. Saudi Arabia Vulvar Cancer Market Outlook
    - 9.3.1.1. Market Size & Forecast
      - 9.3.1.1.1. By Value
    - 9.3.1.2. Market Share & Forecast
      - 9.3.1.2.1. By Cancer Type
      - 9.3.1.2.2. By Treatment Type
      - 9.3.1.2.3. By End-User
  - 9.3.2. UAE Vulvar Cancer Market Outlook
    - 9.3.2.1. Market Size & Forecast
      - 9.3.2.1.1. By Value
    - 9.3.2.2. Market Share & Forecast
      - 9.3.2.2.1. By Cancer Type
      - 9.3.2.2.2. By Treatment Type
      - 9.3.2.2.3. By End-User
  - 9.3.3. South Africa Vulvar Cancer Market Outlook
    - 9.3.3.1. Market Size & Forecast
      - 9.3.3.1.1. By Value

- 9.3.3.2. Market Share & Forecast
  - 9.3.3.2.1. By Cancer Type
  - 9.3.3.2.2. By Treatment Type
  - 9.3.3.2.3. By End-User

## **10. SOUTH AMERICA VULVAR CANCER MARKET OUTLOOK**

- 10.1. Market Size & Forecast
  - 10.1.1. By Value
- 10.2. Market Share & Forecast
  - 10.2.1. By Cancer Type
  - 10.2.2. By Treatment Type
  - 10.2.3. By End-User
  - 10.2.4. By Country
- 10.3. South America: Country Analysis
  - 10.3.1. Brazil Vulvar Cancer Market Outlook
    - 10.3.1.1. Market Size & Forecast
      - 10.3.1.1.1. By Value
    - 10.3.1.2. Market Share & Forecast
      - 10.3.1.2.1. By Cancer Type
      - 10.3.1.2.2. By Treatment Type
      - 10.3.1.2.3. By End-User
  - 10.3.2. Colombia Vulvar Cancer Market Outlook
    - 10.3.2.1. Market Size & Forecast
      - 10.3.2.1.1. By Value
    - 10.3.2.2. Market Share & Forecast
      - 10.3.2.2.1. By Cancer Type
      - 10.3.2.2.2. By Treatment Type
      - 10.3.2.2.3. By End-User
  - 10.3.3. Argentina Vulvar Cancer Market Outlook
    - 10.3.3.1. Market Size & Forecast
      - 10.3.3.1.1. By Value
    - 10.3.3.2. Market Share & Forecast
      - 10.3.3.2.1. By Cancer Type
      - 10.3.3.2.2. By Treatment Type
      - 10.3.3.2.3. By End-User

## **11. MARKET DYNAMICS**

- 11.1. Drivers
- 11.2. Challenges

## **12. MARKET TRENDS & DEVELOPMENTS**

- 12.1. Merger & Acquisition (If Any)
- 12.2. Product Launches (If Any)
- 12.3. Recent Developments

## **13. GLOBAL VULVAR CANCER MARKET: SWOT ANALYSIS**

## **14. PORTER'S FIVE FORCES ANALYSIS**

- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Products

## **15. COMPETITIVE LANDSCAPE**

- 15.1. Merck & Co. Inc.
  - 15.1.1. Business Overview
  - 15.1.2. Products & Services
  - 15.1.3. Recent Developments
  - 15.1.4. Key Personnel
  - 15.1.5. SWOT Analysis
- 15.2. Sanofi SA
- 15.3. Novartis AG
- 15.4. Astellas Pharma Inc.
- 15.5. Pfizer Inc.
- 15.6. Abbott Laboratories
- 15.7. Bristol-Myers Squibb Company
- 15.8. Takeda Pharmaceutical Company Limited
- 15.9. F. Hoffmann-La Roche Ltd
- 15.10. Eli Lilly and Company

## **16. STRATEGIC RECOMMENDATIONS**

## 17. ABOUT US & DISCLAIMER

## I would like to order

Product name: Vulvar Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Cancer Type (Vulvar Squamous Cell Carcinoma, Vulvar Melanoma, Adenocarcinoma, Basal Cell Carcinoma), By Treatment Type (Chemotherapy, Surgery, Laser Surgery, Excision, Skinning Vulvectomy, Radical Vulvectomy, Radiation Vulvectomy, Biologic Therapy), By End-User (Hospitals & Clinics, Research & Academic Institutes, Others), By Region & Competition, 2021-2031F

Product link: <https://marketpublishers.com/r/V19E8D03A277EN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V19E8D03A277EN.html>